title: Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
abstract: To date there is a substantial experience with rapamycin conversion in stable renal transplant recipients with respect to the procedure of conversion, initial doses, and target blood levels as well as adverse events, but in the case of Everolimus there is almost no experience with conversion and calcineurin inhibitor (CNI) withdrawal. We describe an initial experience among 32 renal transplant recipients who were converted to Everolimus with complete suspension of CNI in two Spanish transplant centers. Our results emphasised the procedure for conversion, the target levels, the adverse events, and the initial efficacy, over the first month after conversion. Our conclusions were that conversion from CNI to Everolimus was a simple, safe procedure with a predictable profile of adverse events, which were, in general, of mild intensity. There was a good correlation between initial dose and blood level. Initial doses of about 3 mg/d combined with rapid reduction in CNI exposure seemed to be adequate. The target range levels between 5 and 10 ng/mL seemed to be sufficient for complete CNI elimination, especially in patients also receiving antiproliferative drugs (such as mycophenolate mofetil or azathioprine) in whom levels near the lower end of the range might be adequate.
authors.affiliation: H.U. Valdecilla, Santander, Spain. ruizjc@humv.es
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
authors.forename: A
authors.initials: A
authors.lastname: Sanchez-Fructuoso
authors.forename: E
authors.initials: E
authors.lastname: Rodrigo
authors.forename: J
authors.initials: J
authors.lastname: Conesa
authors.forename: J G
authors.initials: JG
authors.lastname: Cotorruelo
authors.forename: C
authors.initials: C
authors.lastname: Gómez-Alamillo
authors.forename: N
authors.initials: N
authors.lastname: Calvo
authors.forename: A
authors.initials: A
authors.lastname: Barrientos
authors.forename: M
authors.initials: M
authors.lastname: Arias
mesh_terms: D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D000068338:Everolimus; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; D003404:Creatinine; D020123:Sirolimus